PIN84 Health State Utilities of Risks Associated with Antiretroviral Treatment for Human Immunodeficiency Virus (Hiv)  by Matza, LS et al.
A590  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
8 in 10 HIV positive patients’ lost-to-follow up adhere to ART. Interventions such 
as comprehensive HIV training targeting health worker attitudes and perceptions 
of HIV positive patients such as pre- and post HIV test counseling may further 
improve ART adherence.
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Objectives: The scale up of HIV services and access to anti-retroviral therapy in 
Africa has been made possible in the last 10 years. However, it is important that 
more sustainable “in country” options are explored for sustainability of services. 
The adult HIV clinic at the Infectious Diseases Institute (IDI) in Kampala, Uganda 
has approximately 8000 registered patients who receive care free of charge. We are 
exploring the possibility that some patients are willing /able to contribute to the 
cost of their care. Our objective was to explore attitudes and perceptions of patients 
and staff towards using a fee-based “after hours” clinic (AHC) at IDI. MethOds: We 
employed a cross-sectional, qualitative design. A purposeful sample of 188 adults 
which included current HIV clients and IDI staff was stratified by gender and age. We 
conducted 14 focus group discussions and 55in-depth interviews. Thematic content 
analysis was conducted and Nvivo Software used to manage data. Results: There 
were six key themes that emerged regarding participant perceptions of the AHC. 
Access to care (positive and negative), benefits and disadvantages of an AHC, key 
categories of health care services, recommending the service to friends, sliding scale 
fee-for-service, and suggestions to improve service delivery. Results suggested that 
some respondents were willing to pay for consultation, brand-name drugs, lab tests 
and other services. All were willing to recommend friends/ relatives. Respondents 
agreed that, as a sign of social responsibility, some money could be used to help 
underprivileged patients cOnclusiOns: Our AHC clinic is perceived as beneficial 
to patients because it provides access to HIV services at convenient times. Many 
patients are willing to pay for this enhanced service. Promotion of quality private-
public partnerships aiming to sustain quality HIV services in Uganda should be 
encouraged.
PIN84
HEAltH stAtE utIlItIEs of rIsks AssocIAtEd wItH ANtIrEtrovIrAl 
trEAtmENt for HumAN ImmuNodEfIcIENcy vIrus (HIv)
Matza LS1, Chung KC2, Kim KJ1, Paulus T3, Davies EW4, Stewart KD1, McComsey GA5, 
Fordyce M2
1Evidera, Bethesda, MD, USA, 2Gilead Sciences, Inc, Foster City, CA, USA, 3University of Georgia, 
Athens, GA, USA, 4Evidera, London, UK, 5Case Western Reserve University, Cleveland, OH, USA
Objectives: People with human immunodeficiency virus (HIV) have increased risk 
of cardiovascular disease (CVD), kidney disease, and low bone mineral density. Some 
antiretroviral therapies (ART) further increase the risk of these events. The purpose of 
this study was to estimate health state utilities associated with these risks so that the 
values may be used in cost-utility models. MethOds: Qualitative thematic analysis 
was conducted to examine 4,122 messages posted to the POZ/AIDSmeds Internet 
Community Forums from 2008 to 2014. This analysis assessed member awareness of, 
concerns about, and treatment changes due to bone, kidney, and heart-related side 
effects and risks of HIV/AIDS medications. Then, health state vignettes were drafted 
based on this qualitative analysis, literature review, and clinician interviews. The 
health states (representing HIV, plus treatment-related risks) were valued in time 
trade-off (TTO) interviews with general population participants in the UK (London, 
Edinburgh). Results: Quantitative analysis of the Internet forums documented 
patient concerns about ART risks, as well as treatment decisions made because of 
these risks. A total of 208 participants completed utility interviews (51.4% female; 
mean age 44.6y). The mean (SD) utility of the basic HIV health state (describing a viro-
logically suppressed patient treated with ART) was 0.86 (0.14). Adding a description 
of risk to this basic health state was associated with statistically significant disutility 
(i.e., utility decreases): risk of renal problems (disutility = -0.02), risk of bone problems 
(-0.03), and risk of myocardial infarction (-0.05). Health states including the medical 
conditions themselves, rather than risk, had larger disutilities (e.g., stage 4 chronic 
kidney disease; disutility = -0.19). cOnclusiOns: The vignette-based TTO method 
was feasible for quantifying the utility impact of ART-related risks, demonstrating 
small but consistent disutilities. These disutilities may be used in cost-utility models 
comparing the value of treatments for patients with HIV.
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Objectives: The introduction of effective ART in HIV has led to substantial reduc-
tions in morbidity and mortality. However adverse events (AEs) associated with ARTs 
can lead to discontinuation, and worsening of health-related quality of life (HRQL). 
This study aimed to elicit societal disutility values for CNS side effects associated 
with ARTs in France. MethOds: Health states (HS) were developed from interviews 
with HIV patients (N= 9) and one specialist clinician in France. HS were developed to 
describe a stable HIV health state (on treatment), and nine CNS side effects associated 
with ARTs (abnormal dreams, insomnia, anxiety and depression, suicidal thoughts, 
balance and coordination problems, attention difficulties, dizziness, headaches and 
somnolence). Draft HS were reviewed and refined in interviews with patients and 
clinicians (N= 4 in total). The revised HS were piloted with general public to check 
understanding and then evaluated by 100 members of the public in France using 
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Objectives: Annual trivalent influenza vaccines (TIV) containing three influenza 
strains (A/H1N1, A/H3N2, and one B) have been recommended in Panama since 2006. 
However, worldwide co-circulation of two distinct B lineages (Victoria and Yamagata) 
and difficulties in predicting which lineage will predominate in the next season have 
led to the development of quadrivalent influenza vaccines (QIV) including both B 
lineages. Our analysis evaluates the public health and economic benefits of using 
QIV versus TIV in Panama from 2006 to 2013. MethOds: A static model published 
by Reed et al. in 2012 was adapted to Panama and stratified by age group. In addition, 
B-lineage cross-protection was included based on published sources. We calculated 
the hypothetical impact of QIV compared with TIV over seven influenza seasons 
(2009 pandemic year excluded) using virologic circulation, vaccine coverage, vaccine 
effectiveness and attack rate. In absence of B-lineage distribution in Panama, Brazilian 
data were considered. For influenza-related outcomes (outpatient visits, hospitalisa-
tions, deaths), two sets of inputs were used. Influenza-related costs were estimated 
from societal perspective in Panamanian balboas (1 per US dollar). Results: Over 
the 2006-2013 period, QIV would have prevented 7,519 influenza B cases compared 
with TIV, averting between 2,756 and 5,564 outpatients visits, between 28 and 2,202 
hospitalisations and between 6 and 930 deaths. This translates into influenza-related 
avoided costs of between 137 and 3,599 thousand balboas. In 2012, year with high 
B circulation and mismatch, QIV would have avoided 5,256 cases, 3,889 outpatient 
visits, 1,539 hospitalisations, 650 deaths and 2.5 million balboas of influenza-related 
costs in the upper bound. cOnclusiOns: The wider protection offered by QIV would 
reduce the number of influenza infections and its related complications, leading to 
influenza-related costs avoided. Herd effect was not taken into account, underesti-
mating the benefits of QIV vaccination. More robust local data are needed to better 
assess benefits of QIV.
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Objectives: Annual trivalent influenza vaccines (TIV) containing three influenza 
strains (A/H1N1, A/H3N2, and one B) have been recommended in Colombia since 
2007. However, worldwide co-circulation of two distinct B lineages (Victoria and 
Yamagata) and difficulties in predicting which lineage will predominate in the 
next season have led to the development of quadrivalent influenza vaccines (QIV) 
including both B lineages. Our analysis evaluates the public health and economic 
benefits of using QIV versus TIV in Colombia from 2007 to 2014. MethOds: A 
static model published by Reed et al. in 2012 was adapted to Colombia and strati-
fied by age group. In addition, B-lineage cross-protection was included based on 
published sources. We calculated the hypothetical impact of QIV compared with 
TIV over seven influenza seasons (2009 pandemic year excluded) using virologic 
circulation, vaccine coverage, vaccine effectiveness and attack rate. In absence of 
B-lineage distribution in Colombia for 2007-2013, Brazilian data were considered. 
For influenza-related outcomes (outpatient visits, hospitalisations, deaths), two 
input sets were used. Influenza-related costs were estimated from societal per-
spective in Colombian pesos (0.00052 per US dollar in 2013). Results: Over the 
2007-2014 period, QIV would have prevented 27,957 influenza B cases compared 
with TIV, averting between 10,450 and 19,188 outpatient visits, between 492-7,549 
hospitalisations and between 31-2,028 deaths. This translates into influenza-related 
avoided costs of between 1.7 and 12.5 billion pesos. In 2014, year with high B circula-
tion and mismatch, QIV would have avoided 14,771 cases, 10,138 outpatient visits, 
3,989 hospitalisations, 1,071 deaths and 6.6 billion pesos of influenza-related costs 
in the upper bound. cOnclusiOns: The wider protection offered by QIV would 
reduce the number of influenza infections and its related complications, leading 
to influenza-related costs avoided. Herd effect was not taken into account, under-
estimating the benefits of QIV vaccination. More robust local data are needed to 
better assess benefits of QIV.
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Objectives: To determine the level of adherence to ART among HIV positive 
patients lost-to-follow in an HIV clinic in a private-for-profit health facility in 
Kampala district, Uganda. MethOds: A cross-sectional study design was con-
ducted in an HIV clinic in Kampala district. Medical records of 550 HIV positive 
attending the HIV clinic from April 2005 to April 2012 in a private-for-profit health 
facility were analyzed. Per ART dataset, 147 HIV positive patients were identified as 
being lost-to-follow up to HIV care among which 94 were accessible for interviews. 
Loss-to-follow up was regarded as HIV positive patients who had not attended 
ART clinic for a period or 4 or more months. A telephone interview was conducted 
using a pretested structured questionnaire in order to assess adherence to ART and 
factors associated with loss to follow up from the ART clinic. Results: The level of 
adherence to ART was 77.7% while level of loss to follow up was 26.7%. Predictors of 
adherence to ART were; distance from health facility (AOR = 0.01, 95% CI = 0.00-0.35), 
health worker attitude (AOR = 9.43, 95% CI = 1.55 – 57.43) and patients perception of 
lifetime ART medication (AOR = 26.54, 95% CI = 3.33 – 211.2) cOnclusiOns: About 
